European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - oestrogens conjugated, bazedoxifene - postmenopause - conjugated estrogens and bazedoxifene - duavive is indicated for:treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.the experience treating women older than 65 years is limited.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - bazedoxifene acetate; conjugated oestrogens - modified-release tablet - 20mg ; 450microgram

Canada - English - Health Canada

pfizer canada ulc - conjugated estrogens; bazedoxifene (bazedoxifene acetate) - tablet (immediate and extended release) - 0.45mg; 20mg - conjugated estrogens 0.45mg; bazedoxifene (bazedoxifene acetate) 20mg - estrogen agonist-antagonists

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - bazedoxifene acetate; estrogens conjugated - tablets modified release - bazedoxifene acetate 20 mg; estrogens conjugated 0.45 mg - conjugated estrogens and bazedoxifene - treatment of the following conditions in women with a uterus:• treatment of moderate to severe vasomotor symptoms associated with menopause• prevention of postmenopausal osteoporosis